This study endeavors to develop and validate an integrated biomarker signature (IBS) grounded in serum carbohydrate antigen 72-4 (CA72-4), vascular endothelial growth factor-C (VEGF-C), and the pepsinogen I/II ratio (PGI/PGII). Here, VEGFC is linked to irritable bowel syndrome.